ArticleESC heart failure2022
Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.
Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Quantitative CMR-derived pulmonary circulation imaging biomarkers in recent-onset dilated cardiomyopathy associated with pulmonary hemodynamics and clinical improvement.BMC medical imaging · 2026Article
- Identification of disease-associated gene expression signatures for mechanistic insights and drug prediction in dilated cardiomyopathy-induced heart failure.Molecular and cellular biochemistry · 2026Article
- The Impact of Cardio-Renal-Metabolic Profile in Dilated Cardiomyopathy.Current cardiology reports · 2025Review
- Dilated cardiomyopathy signature metabolic marker screening: Machine learning and multi-omics analysis.Heliyon · 2025Article
- One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India.Nature communications · 2025Article
- Genotype is associated with left ventricular reverse remodelling and early events in recent-onset dilated cardiomyopathy.ESC heart failure · 2024Article
- Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.ESC heart failure · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to evaluate the outcome and prognostic factors in patients with dilated cardiomyopathy (DCM) and long-standing heart failure (LDCM) vs. recent-onset heart failure (RODCM). METHODS AND
resultsWe compared 2019 patients with RODCM (duration <6 months, mean age 58.6 years, 70.7% male) with 1714 patients with LDCM (duration ≥6 months, median duration 3.5 years, mean age 62.5 years, 73.7% male) included in the Swedish Heart Failure Registry in the years 2003-16. Outcome measures were all-cause, cardiovascular (CV), and non-CV death and hospitalizations; heart transplantation; and a combined outcome of all-cause death, heart transplantation, or heart failure (HF) hospitalization. Multivariable risk factor analyses were performed for the combined endpoint. All outcomes were more frequent in LDCM than in RODCM. The multivariable-adjusted hazard ratios (HRs) (95% confidence interval) for LDCM vs. RODCM were 1.56 (1.34-1.82), P < 0.0001, for all-cause death over a median follow-up of 4.2 and 5.0 years, respectively; 1.67 (1.36-2.05), P < 0.0001, for CV death; 2.12 (1.14-3.91), P < 0.0001, for heart transplantation; 1.36 (1.21-1.53), P < 0.0001, for HF hospitalization; and 1.37 (1.24-1.52), P < 0.0001, for the combined outcome. A propensity score-matched analysis yielded similar results. CV death was the main cause of mortality in LDCM and was higher in LDCM than in RODCM (P < 0.0001). Almost all co-morbidities were significantly more frequent in LDCM than in RODCM, and the mean number of co-morbidities increased significantly with increased duration of disease, also after age adjustment. Age, New York Heart Association functional class, ejection fraction, and left bundle branch block were prognostically adverse. The only co-morbidity associated with the combined outcome regardless of HF duration was diabetes, in LDCM [HR 1.34 (1.15-1.56), P = 0.0002] and in RODCM [HR 1.29 (1.04-1.59), P = 0.018]. Male sex [HR 1.38 (1.18-1.63), P < 0.0001] and aspirin use [HR 1.33 (1.14-1.55), P = 0.0004] carried increased risk only in RODCM. Heart rate ≥75 b.p.m. [HR 1.20 (1.04-1.37), P = 0.01], atrial fibrillation [HR 1.24 (1.08-1.42), P = 0.0024], musculoskeletal or connective tissue disorder [HR 1.36 (1.13-1.63), P = 0.0014], and diuretic therapy [HR 1.40 (1.17-1.67), P = 0.0002] were prognostically adverse only in LDCM.
conclusionsThis nationwide study of patients with DCM demonstrates that longer disease duration is associated with worse prognosis. Co-morbidities are more common in long-standing HF than in recent-onset HF and are associated with worse outcome. With the increased survival seen in the last decades, our results highlight the importance of careful attention to co-morbid conditions in patients with DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.